CSL Limited (OTCMKTS:CSLLY) is a global biotechnology company specializing in the development, manufacture and distribution of therapies derived from human plasma and vaccines. Headquartered in Melbourne, Australia, the company operates through two primary business units: CSL Behring, which focuses on plasma-derived and recombinant therapies, and Seqirus, which develops and supplies influenza vaccines. CSL’s product portfolio addresses serious and chronic medical conditions, including immunodeficiencies, bleeding disorders and hereditary angioedema, as well as seasonal and pandemic influenza.
CSL Behring offers a range of immunoglobulins, albumin products and clotting factors, serving patients with rare and life-threatening conditions. Its research and development activities are aimed at expanding indications for existing therapies and advancing next-generation protein engineering. Seqirus, acquired in 2015, has grown into one of the world’s largest influenza vaccine providers, offering both egg-based and cell-based vaccine technologies, as well as novel adjuvant formulations to enhance immune response.
With manufacturing facilities and research centers in North America, Europe and the Asia-Pacific region, CSL supports a global supply chain that serves millions of patients in over 60 countries. The company collaborates with governments, public health organizations and academic institutions to ensure broad access to critical therapies and to strengthen preparedness for emerging infectious diseases.
Founded in 1916 as Commonwealth Serum Laboratories under the Australian government, CSL was privatized and listed on the Australian Securities Exchange in 1994. Today, it is led by CEO Paul Perreault, who continues to drive innovation and global expansion while maintaining a focus on patient safety and quality standards across its operations.
AI Generated. May Contain Errors.
Free CSLLY Stock Alerts